Previous 10 | Next 10 |
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
Koss Corporation (KOSS) is expected to report for Q2 2024 Waterstone Financial Inc. (WSBF) is expected to report for Q4 2023 Silver Bull Resources Inc (SVBL) is expected to report for quarter end 2023-10-31 Xcel Energy Inc. (XEL) is expected to report $0.85 for Q4 2023 Sodexo ADR ...
- Interviews with patients from the VenoValve® pivotal study - Materials now available on the Company's website IRVINE, CA / ACCESSWIRE / December 14, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the trea...
No Deaths or Pulmonary Embolisms Occurring During the 30 Day MAE Period Expected Overall Device-Related Material Adverse Event Rate of 8% for the Fully Enrolled 75 Patient Study Six (6) DVT Related MAEs IRVINE, CA / ACCESSWIRE / November 16, 2023 / enVVeno Medical Corporation (Nas...
2023-10-26 17:21:50 ET More on enVVeno Medical Seeking Alpha’s Quant Rating on enVVeno Medical Historical earnings data for enVVeno Medical Financial information for enVVeno Medical For further details see: enVVeno Medical files to sell 14.71M shar...
- $51.4 million cash on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025 - Achieved full enrollment for VenoValve® U.S. pivotal trial - Expedited development plan for the enVVe® transcatheter-based replacement ven...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
enVVeno Medical Corporation (NVNO) is expected to report for Q3 2023
Live moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, October 25 th at 12:00 PM ET IRVINE, CA / ACCESSWIRE / October 12, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for t...
2023-10-06 10:35:53 ET More on Health Care Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities: ...
News, Short Squeeze, Breakout and More Instantly...
enVVeno Medical Corp Com Company Name:
NVNO Stock Symbol:
NASDAQ Market:
enVVeno Medical Corp Com Website:
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27 th at 4:00 PM ET IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatmen...
91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved 100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed 89% of Venous Ulcers with a Duration of More Than One Year Prior to Veno...
IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be ...